CD37 in B Cell Derived Tumors—More than Just a Docking Point for Monoclonal Antibodies

CD37 is a tetraspanin expressed prominently on the surface of B cells. It is an attractive molecular target exploited in the immunotherapy of B cell-derived lymphomas and leukemia. Currently, several monoclonal antibodies targeting CD37 as well as chimeric antigen receptor-based immunotherapies are...

Descripción completa

Detalles Bibliográficos
Autores principales: Bobrowicz, Malgorzata, Kubacz, Matylda, Slusarczyk, Aleksander, Winiarska, Magdalena
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7765243/
https://www.ncbi.nlm.nih.gov/pubmed/33333768
http://dx.doi.org/10.3390/ijms21249531
_version_ 1783628446167990272
author Bobrowicz, Malgorzata
Kubacz, Matylda
Slusarczyk, Aleksander
Winiarska, Magdalena
author_facet Bobrowicz, Malgorzata
Kubacz, Matylda
Slusarczyk, Aleksander
Winiarska, Magdalena
author_sort Bobrowicz, Malgorzata
collection PubMed
description CD37 is a tetraspanin expressed prominently on the surface of B cells. It is an attractive molecular target exploited in the immunotherapy of B cell-derived lymphomas and leukemia. Currently, several monoclonal antibodies targeting CD37 as well as chimeric antigen receptor-based immunotherapies are being developed and investigated in clinical trials. Given the unique role of CD37 in the biology of B cells, it seems that CD37 constitutes more than a docking point for monoclonal antibodies, and targeting this molecule may provide additional benefit to relapsed or refractory patients. In this review, we aimed to provide an extensive overview of the function of CD37 in B cell malignancies, providing a comprehensive view of recent therapeutic advances targeting CD37 and delineating future perspectives.
format Online
Article
Text
id pubmed-7765243
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-77652432020-12-27 CD37 in B Cell Derived Tumors—More than Just a Docking Point for Monoclonal Antibodies Bobrowicz, Malgorzata Kubacz, Matylda Slusarczyk, Aleksander Winiarska, Magdalena Int J Mol Sci Review CD37 is a tetraspanin expressed prominently on the surface of B cells. It is an attractive molecular target exploited in the immunotherapy of B cell-derived lymphomas and leukemia. Currently, several monoclonal antibodies targeting CD37 as well as chimeric antigen receptor-based immunotherapies are being developed and investigated in clinical trials. Given the unique role of CD37 in the biology of B cells, it seems that CD37 constitutes more than a docking point for monoclonal antibodies, and targeting this molecule may provide additional benefit to relapsed or refractory patients. In this review, we aimed to provide an extensive overview of the function of CD37 in B cell malignancies, providing a comprehensive view of recent therapeutic advances targeting CD37 and delineating future perspectives. MDPI 2020-12-15 /pmc/articles/PMC7765243/ /pubmed/33333768 http://dx.doi.org/10.3390/ijms21249531 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Bobrowicz, Malgorzata
Kubacz, Matylda
Slusarczyk, Aleksander
Winiarska, Magdalena
CD37 in B Cell Derived Tumors—More than Just a Docking Point for Monoclonal Antibodies
title CD37 in B Cell Derived Tumors—More than Just a Docking Point for Monoclonal Antibodies
title_full CD37 in B Cell Derived Tumors—More than Just a Docking Point for Monoclonal Antibodies
title_fullStr CD37 in B Cell Derived Tumors—More than Just a Docking Point for Monoclonal Antibodies
title_full_unstemmed CD37 in B Cell Derived Tumors—More than Just a Docking Point for Monoclonal Antibodies
title_short CD37 in B Cell Derived Tumors—More than Just a Docking Point for Monoclonal Antibodies
title_sort cd37 in b cell derived tumors—more than just a docking point for monoclonal antibodies
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7765243/
https://www.ncbi.nlm.nih.gov/pubmed/33333768
http://dx.doi.org/10.3390/ijms21249531
work_keys_str_mv AT bobrowiczmalgorzata cd37inbcellderivedtumorsmorethanjustadockingpointformonoclonalantibodies
AT kubaczmatylda cd37inbcellderivedtumorsmorethanjustadockingpointformonoclonalantibodies
AT slusarczykaleksander cd37inbcellderivedtumorsmorethanjustadockingpointformonoclonalantibodies
AT winiarskamagdalena cd37inbcellderivedtumorsmorethanjustadockingpointformonoclonalantibodies

Ejemplares similares